| 名稱 | AI-Edigene® ABL1 p.T315I Reference Standard P |
| 型號(hào) | CBP10519 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | AI-Edigene® ABL1 p.T315I Reference Standard Plus |
產(chǎn)品搜索
相關(guān)文章
- CYP2C19基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- 治療疼痛的潛力靶點(diǎn)——NGF
- 細(xì)胞株開發(fā)的主要過程要知道
- BCMA靶點(diǎn)藥物細(xì)胞篩選模型
- 【連載-企業(yè)參考品】 急性淋巴細(xì)胞白血病的診斷參考品的選擇
- 實(shí)驗(yàn)?zāi)芊裰貜?fù)仍在持續(xù)：誰(shuí)來(lái)給韓春雨事件畫上句號(hào)？
- ATCC細(xì)胞單純的固定液一般難以達(dá)到這些要求
- ATCC細(xì)胞株開發(fā)的四階段簡(jiǎn)介
- PD-1/L1 &4-1BB雙靶點(diǎn)細(xì)胞篩選模型
- 基于納米顆粒的組合免疫療法對(duì)致命性癌癥發(fā)起三重打擊
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
基因檢測(cè)標(biāo)準(zhǔn)品 > Mutation > CBP10519AI-Edigene® ABL1 p.T315I Reference Standard P
- 詳細(xì)內(nèi)容
CBP10519 | |
| Format | Genomic DNA |
| Description | ABL1 T315I is a gatekeeper mutation that lies within the hinge region of the protein kinase domain of the Abl1 protein (PMID: 18794843). T315I has been demonstrated to occur as a secondary resistance mutation and results in increased kinase activity and transformation in the context of BCR-ABL1 in cell culture (PMID: 11423618, PMID: 18794843, PMID: 27890928), and results in reduced catalytic efficiency (kcat/km) in an in vitro assay (PMID: 30684523), but has not been fully characterized and therefore, its effect on Abl1 protein function is unknown. |
| Technical Data | |
| DNA Change | c.944C>T |
| AA Change | p.T315I |
| Mutation type | Substitution - Missense |
| Zygosity | Homozygous |
| Allelic Frequency | 100.00% |
| Transcript | NM_007313.2 |
| Buffer | Tris-EDTA |
| Product Information | |
| Intended Use | Research Use Only |
| Unit Size | 1ug |
| Concentration | Download for COA |
| Purofication | Download for COA |
| DNA electrophoresis | Download for COA |
| Sanger sequencing |
|
| Storage | 4°C |
| Expiry | 36 months from the date of manufacture |
會(huì)員_a.png)